(ARCT) Arcturus Therapeutics - Ratings and Ratios

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a clinical-stage biopharmaceutical company specializing in the development of innovative messenger RNA (mRNA) therapeutics and vaccines. Leveraging its proprietary LUNAR lipid-mediated delivery and STARR mRNA technologies, the company focuses on addressing infectious diseases and rare liver and respiratory conditions. ARCT-810, an mRNA-based therapeutic for ornithine transcarbamylase deficiency, is in Phase 2 trials, while ARCT-154, an mRNA COVID-19 vaccine, has advanced to Phase 3 in Vietnam. The pipeline also includes ARCT-032 for cystic fibrosis and ARCT-2301, a bivalent COVID-19 vaccine in Phase 3. Additionally, ARCT-2303 and ARCT-2138 are in earlier stages, with LUNAR-FLU in preclinical development for influenza. Founded in 2013, Arcturus is headquartered in San Diego, California, and emphasizes strategic collaborations to enhance its mRNA platform.

From a financial perspective, Arcturus has a market capitalization of approximately $489 million, with a forward P/E of 2.48, indicating expectations for future growth despite current losses. The stock, trading at $16.06, shows a SMA20 of 16.76 and SMA50 of 16.88, suggesting a consolidative trend. With an ATR of 1.30, moderate volatility is anticipated. Over the next three months, the stock is expected to range between $14 and $18, reflecting a neutral to slightly bearish outlook. This forecast is supported by the companys investment in R&D and the absence of immediate catalysts for significant upward movement.